August 8, 2008
Altea Therapeutics Forms Premier Scientific Advisory Board
Altea Therapeutics announced today that several pre-eminent medical practitioners and scientists in the fields of drug delivery, skin physiology, engineering, and clinical medicine have joined its new Scientific Advisory Board. Professor Richard H. Guy, PhD, of the University of Bath in the United Kingdom has been appointed Chair of the Scientific Advisory Board.
Members of the Scientific Advisory BoardRichard H. Guy, PhD is a leading scientist in the physicochemical characterization of transport phenomena in biological membranes and in theoretically defining transdermal drug delivery processes. He is Professor and Head of the Department of Pharmacy & Pharmacology, University of Bath in the United Kingdom.
Mark R. Prausnitz, PhD is a foremost scholar in the fields of drug and vaccine delivery to the skin. He is a Professor at the School of Chemical and Biomolecular Engineering, Georgia Institute of Technology where he and his team research, develop and characterize novel biophysical methods for administering drugs.
David J. Enscore, PhD managed the commercial development of four controlled release pharmaceuticals while at ALZA, a leading drug delivery company subsequently acquired by Johnson & Johnson. He was formerly SVP Product Research and Development at Altea Therapeutics and is an inventor on 25 U.S. patents in drug delivery and medical devices.
Walter M. Holleran, PharmD is a world expert in epidermal structure, lipid metabolism and barrier function. He is Adjunct Professor of Dermatology and Pharmaceutical Chemistry in the Schools of Medicine and Pharmacy at the University of California - San Francisco, as well as Research Chemist at the Department of Veterans Affairs Medical Center in San Francisco.
Jay S. Skyler, MD is a pioneering clinical researcher and international thought leader in the diabetes field. He has played a pivotal role in developing the concepts of intensive insulin therapy. He has served both as President and Director of the American Diabetes Association, and is currently chairman of multiple NIH-sponsored, nationwide clinical studies focused on the treatment and prevention of type 1 diabetes. Dr. Skyler is Professor of Medicine at the University of Miami.
Richard L. Gallo, MD, PhD is a leading investigator in the field of skin research with a focus on the role of the innate immune system in skin health and disease, the role of antimicrobial peptides and aspects of the interaction of the skin with the immune system. Dr Gallo is Professor and Chief of Dermatology at the University of California, San Diego.
Brian B. Hoffman, MD is a Professor of Medicine at Harvard Medical School in Boston. He is an Emeritus Professor of Medicine at Stanford University where he was on the faculty for more than 20 years. He is also the former Chief of Medicine in the VA Boston Health Care System. Dr Hoffman is a clinical pharmacologist with a long-standing research interests in signaling mechanisms of G-protein-coupled receptors in vascular smooth muscle cells, and in the effects of drugs on the cardiovascular system in humans.
"Now that our novel transdermal delivery technology is demonstrating clinical effectiveness for drugs that were previously administered as injections, it is timely to establish the SAB to review and guide the Company's approaches to applying its technology in numerous clinical areas," said Eric Tomlinson, PhD, DSc, President and CEO of Altea Therapeutics. "We anticipate that the SAB will be most valuable in helping to reinforce the Company's scientific capabilities and in selecting and guiding its product development programs."
About Altea Therapeutics
Altea Therapeutics is an emerging specialty pharmaceutical company developing and commercializing products based on a new transdermal patch technology that can deliver therapeutic levels of water-soluble small drugs, therapeutic proteins, carbohydrates, and vaccines through the skin in a convenient, painless and cost-effective manner. Altea Therapeutics has demonstrated in several clinical studies that its patented PassPort(TM) Transdermal System achieves what existing transdermal patches are unable to do, namely the delivery through the skin of compounds that are typically administered by needle injections.
The company is currently conducting clinical trials in the United States for its products, which include a Transdermal Basal Insulin Patch designed to provide continuous delivery of insulin for people with type 1 and type 2 diabetes and a Transdermal Fentanyl Citrate Patch that enables rapid and safe management of moderate to severe pain. Furthermore, the company is in clinical and pre-clinical development with a number of product candidates, including an undisclosed transdermal protein patch, a parathyroid hormone transdermal patch for osteoporosis, and an atypical antipsychotic transdermal patch for the management of psychosis.
Altea Therapeutics is the recipient of the Frost & Sullivan 2007 Technology Innovation Award for its development of the PassPort System and was named one of the top 50 technology companies in the Southeast of the U.S. in 2008 by TechJournal South.
Additional information about Altea Therapeutics may be found at www.alteatherapeutics.com.
NOTE: Altea Therapeutics, PassPort, Medicines Made Better. are either registered trademarks or trademarks of Altea Therapeutics Corporation, in the USA and/or other countries. All other brand names, product names, or trademarks belong to their respective holders.
The statements in this press release regarding the products of Altea Therapeutics in development, product development plans, and projected financial results, are forward-looking statements involving risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to, the ability of Altea Therapeutics to both complete the design, development, and manufacturing process development of its products, manufacture and commercialize its products, obtain product and manufacturing approvals from regulatory agencies, manage its growth and expenses, finance its activities and operations, as well as marketplace acceptance of its products.